Zymeworks inks $187M Merck deal on bi-specific antibodies

Vancouver-based Zymeworks has struck a deal to put its platform technology to work developing bi-specific antibodies for Merck. The biotech gets an unspecified upfront payment, $187 million in potential milestones and tiered royalties on any approved drugs.

Zymeworks' bi-specific antibodies are designed to bind to two different targets, making them effective against a pair of ailments such as cancer and autoimmune disorders. "Zymeworks' technology platform has the potential to provide a unique solution for engineering novel antibodies," said Richard Murray, senior vice president, biologics research at Merck.

"This is an important validation of our scientific leadership in the field of structure-guided protein engineering," Zymeworks' CEO Ali Tehrani said, "and we look forward to working with Merck to [realize] the full value of this novel platform technology across a range of therapeutic indications."

- here's the Zymeworks release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.